Abstract
The progression of fibrosis in non-alcoholic steatohepatitis, NASH has been linked to intermittent hypoxia and improves with oxygenation. Obeticholic acid, OCA has demonstrated efficacy in the treatment of NASH fibrosis. We studied the dose-responsive effects of OCA on HA, portal vein and hepatic vein flow in porcine liver perfused ex vivo with a cardio-emulation pump, the CaVESWave® system. Increased flow in the HA, which provides over 50 percent of tissue oxygenation to the liver, might explain the beneficial effect of OCA in NASH Funding: The study was supported by an Investigator Initiated grant from Intercept Pharmaceutical Declaration of Interest: None to declare. Ethical Approval: The study was approved by the Ethical Committee – Centura Health Research Committee
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call